Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2020 from OUS - Molecular Genetic Studies of Breast and Ovarian Cancer

17 publications found

Bergholtz H, Lien TG, Swanson DM, Frigessi A, Oslo Breast Cancer Research Consortium (OSBREAC), Daidone MG, Tost J, Wärnberg F, Sørlie T (2020)
Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions
NPJ Breast Cancer, 6, 26
DOI 10.1038/s41523-020-0167-x, PubMed 32577501

Chen C, Wei Y, Wei L, Chen J, Chen X, Dong X, He J, Lin L, Zhu Y, Huang H, You D, Lai L, Shen S, Duan W, Su L, Shafer A, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Wang R, Staaf J, Helland Å, Esteller M, Zhang R et al. (2020)
Epigenome-wide gene-age interaction analysis reveals reversed effects of PRODH DNA methylation on survival between young and elderly early-stage NSCLC patients
Aging (Albany NY), 12 (11), 10642-10662
DOI 10.18632/aging.103284, PubMed 32511103

Egeland NG, Jonsdottir K, Aure MR, Sahlberg K, Kristensen VN, Cronin-Fenton D, Skaland I, Gudlaugsson E, Baak JPA, Janssen EAM (2020)
MiR-18a and miR-18b are expressed in the stroma of oestrogen receptor alpha negative breast cancers
BMC Cancer, 20 (1), 377
DOI 10.1186/s12885-020-06857-7, PubMed 32370743

Escala-Garcia M, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Ashworth A, Auer PL, Auvinen P, Beckmann MW, Beesley J, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Blot W, Bogdanova NV, Bojesen SE, Bolla MK, Børresen-Dale AL, Brauch H, Brenner H, Brucker SY, Burwinkel B, Caldas C, Canzian F et al. (2020)
A network analysis to identify mediators of germline-driven differences in breast cancer prognosis
Nat Commun, 11 (1), 312
DOI 10.1038/s41467-019-14100-6, PubMed 31949161

Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C, Soucy P, Lemaçon A, Lush M, Tyrer JP, Ghoussaini M, Moradi Marjaneh M, Jiang X, Agata S, Aittomäki K, Alonso MR, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V et al. (2020)
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Nat Genet, 52 (1), 56-73
DOI 10.1038/s41588-019-0537-1, PubMed 31911677

Feng H, Gusev A, Pasaniuc B, Wu L, Long J, Abu-Full Z, Aittomäki K, Andrulis IL, Anton-Culver H, Antoniou AC, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, Auer PL, Azzollini J, Balmaña J, Barkardottir RB, Barnes DR, Barrowdale D, Beckmann MW, Behrens S, Benitez J, Bermisheva M et al. (2020)
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status
Genet Epidemiol, 44 (5), 442-468
DOI 10.1002/gepi.22288, PubMed 32115800

Fougner C, Bergholtz H, Norum JH, Sørlie T (2020)
Re-definition of claudin-low as a breast cancer phenotype
Nat Commun, 11 (1), 1787
DOI 10.1038/s41467-020-15574-5, PubMed 32286297

Haakensen VD, Khadse A, Sandhu V, Halvorsen AR, Solberg SK, Jørgensen LH, Brustugun OT, Kure EH, Helland Å (2020)
Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
Int J Cancer
DOI 10.1002/ijc.33121, PubMed 32468587

Knutsen E, Lellahi SM, Aure MR, Nord S, Fismen S, Larsen KB, Gabriel MT, Hedberg A, Bjørklund SS, Oslo Breast Cancer Research Consortium (OSBREAC), Bofin AM, Mælandsmo GM, Sørlie T, Mortensen ES, Perander M (2020)
The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers
Sci Rep, 10 (1), 1277
DOI 10.1038/s41598-020-57759-4, PubMed 31992741

Kyte JA, Andresen NK, Russnes HG, Fretland SØ, Falk RS, Lingjærde OC, Naume B (2020)
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J Transl Med, 18 (1), 269
DOI 10.1186/s12967-020-02421-w, PubMed 32620163

Pladsen AV, Nilsen G, Rueda OM, Aure MR, Borgan Ø, Liestøl K, Vitelli V, Frigessi A, Langerød A, Mathelier A, OSBREAC, Engebråten O, Kristensen V, Wedge DC, Van Loo P, Caldas C, Børresen-Dale AL, Russnes HG, Lingjærde OC (2020)
DNA copy number motifs are strong and independent predictors of survival in breast cancer
Commun Biol, 3 (1), 153
DOI 10.1038/s42003-020-0884-6, PubMed 32242091

Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873

Terkelsen T, Russo F, Gromov P, Haakensen VD, Brunak S, Gromova I, Krogh A, Papaleo E (2020)
Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration
Breast Cancer Res, 22 (1), 73
DOI 10.1186/s13058-020-01295-6, PubMed 32605588

von der Lippe Gythfeldt H, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred Ø, Skjerven H, Schlichting E, Lundgren S, Wist E, Naume B, Kristensen V, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2020)
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
Int J Cancer
DOI 10.1002/ijc.33108, PubMed 32488909

Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Jiang X, O'Mara TA, Zhao N, Bolla MK, Dunning AM, Dennis J, Wang Q, Ful ZA, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Arun BK, Auer PL, Azzollini J, Barrowdale D, Becher H, Beckmann MW et al. (2020)
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
Nat Genet, 52 (6), 572-581
DOI 10.1038/s41588-020-0609-2, PubMed 32424353

Zhang R, Chen C, Dong X, Shen S, Lai L, He J, You D, Lin L, Zhu Y, Huang H, Chen J, Wei L, Chen X, Li Y, Guo Y, Duan W, Liu L, Su L, Shafer A, Fleischer T, Moksnes Bjaanæs M, Karlsson A, Planck M, Wang R, Staaf J et al. (2020)
Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects
Chest (in press)
DOI 10.1016/j.chest.2020.01.048, PubMed 32113923

Zhu Q, Tekpli X, Troyanskaya OG, Kristensen VN (2020)
Subtype-specific transcriptional regulators in breast tumors subjected to genetic and epigenetic alterations
Bioinformatics, 36 (4), 994-999
DOI 10.1093/bioinformatics/btz709, PubMed 31529022

 
Page visits: 410659